Learning to Adapt - Deep Reinforcement Learning in Treatment-Resistant Prostate Cancer

Author:

Gallagher KitORCID,Strobl MaximillianORCID,Gatenby RobertORCID,Maini PhilipORCID,Anderson AlexanderORCID

Abstract

AbstractStandard-of-care treatment regimes have long been designed to for maximal cell kill, yet these strategies often fail when applied to treatment–resistant tumors, resulting in patient relapse. Adaptive treatment strategies have been developed as an alternative approach, harnessing intra-tumoral competition to suppress the growth of treatment resistant populations, to delay or even prevent tumor progression. Following recent clinical implementations of adaptive therapy, it is of significant interest to optimise adaptive treatment protocols. We propose the application of deep reinforcement learning models to provide generalised solutions within adaptive drug scheduling, and demonstrate this framework can outperform the current adaptive protocols, extending time to progression by up to a quarter. This strategy is robust to varying model parameterisations, and the underlying tumor model. We demonstrate the deep learning framework can produce interpretable, adaptive strategies based on a single tumor burden threshold, replicating and informing a novel, analytically–derived optimal treatment strategy with no knowledge of the underlying mathematical tumor model. This approach is highly relevant beyond the simple, analytically–tractable tumor model considered here, demonstrating the capability of deep learning frameworks to help inform and develop treatment strategies in complex settings. Finally, we propose a pathway to integrate mechanistic modelling with DRL to tailor generalist treatment strategies to individual patients in the clinic, generating personalised treatment schedules that consistently outperform clinical standard-of-care protocols.

Publisher

Cold Spring Harbor Laboratory

Reference50 articles.

1. Mechanisms of multidrug resistance in cancer chemotherapy;International Journal of Molecular Sciences,2020

2. Cancer drug resistance: an evolving paradigm

3. Targeting metastatic cancer

4. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy

5. M. C. Perry , The Chemotherapy Source Book, vol. 117. Lippincott Williams & Wilkins, 1992.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3